Alafosalin

Alafosalin

SCHEMBL6908702

CC(N)C(=O)NCCP(=O)(O)O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 7/20 0.45
ALDH1A1 P00352 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
PGK1 P00558 1/20 0.43
PGK2 P07205 1/20 0.43
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
LAP3 P28838 4/20 0.38
ERAP1 Q9NZ08 1/20 0.38
S1PR2 O95136 2/20 0.37
S1PR1 P21453 2/20 0.37
S1PR3 Q99500 2/20 0.37
S1PR5 Q9H228 1/20 0.37
TERT O14746 1/20 0.37
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
DNPEP Q9ULA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alafosalin SCHEMBL1582384 1.00 ANPEP (0.45) ANPEPALDH1A1TDP1PGK1PGK2
SCHEMBL12112086 0.83 PGK1 (0.46) ANPEPALDH1A1TDP1PGK1PGK2
SCHEMBL4948951 0.82 MEN1 (0.52) ANPEPALDH1A1TDP1PGK1PGK2
SCHEMBL14655413 0.81 MEN1 (0.53) ANPEPALDH1A1TDP1
SCHEMBL14159146 0.81 USP2 (0.43) ANPEPALDH1A1USP2TSHRTERT
SCHEMBL30393344 0.81 USP2 (0.43) ANPEPALDH1A1USP2TSHRTERT
SCHEMBL9140084 0.80 USP2 (0.50) ANPEPALDH1A1USP2TSHRTERT
SCHEMBL9140089 0.80 USP2 (0.50) ANPEPALDH1A1USP2TSHRTERT
SCHEMBL24670624 0.80 ALDH1A1 (0.48) ANPEPALDH1A1TDP1PGK1PGK2
Phosphoric Acid SCHEMBL8460247 0.80 USP2 (0.48) ANPEPALDH1A1USP2TSHRLAP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6762174-B1 BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE DOVETAIL TECHNOLOGIES, INC. 2004-07-13 US disclosed
US-6498150-B2 USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS DOVETAIL TECHNOLOGIES, INC. 2002-12-24 US disclosed
US-20020035118-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS DOVETAIL TECHNOLOGIES INC. 2002-03-21 US disclosed
US-6007819-A Methods of inducing immunity using low molecular weight immune stimulants DOVETAIL TECHNOLOGIES, INC. (US) 1999-12-28 US disclosed
WO-1999042097-A1 SMALL MOLECULES THAT ELICIT A POLARIZED TH1 RESPONSE AND FOR MODULATION OF CELLULAR IMMUNITY DOVETAIL TECHNOLOGIES INC. (US) 1999-08-26 WO disclosed
WO-1997014306-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS DOVETAIL TECHNOLOGIES, INC. (US) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035118-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS ACP1, CD14, HPGDS ANPEP 149/4885ALDH1A1 4086/4885TDP1 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.